CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (Nasdaq: ALKS) announced today that the Company has expanded its addiction drug franchise to include a program to develop oral products for the treatment of addiction. As part of this initiative, the Company has commenced enrollment in a clinical trial for an undisclosed oral compound, ALKS 29, a new product candidate for the treatment of alcohol dependence.
